Results for CAR T Cells

1 - 10 of 153

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

E-mail:

weberew [at] chop.edu

Jessica B. Foster, MD

Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.

E-mail:

fosterjb [at] chop.edu

Sarah A. Richman, MD, PhD

Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.

E-mail:

richmans [at] chop.edu

Stephan A. Grupp, MD, PhD

Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.

E-mail:

grupp [at] chop.edu

Regina Myers, MD

Dr. Myers aims to improve outcomes for children and young adults receiving cellular immunotherapies for high-risk hematologic toxicities. Her current research is focused on studying toxicities of CAR T-cell therapies through a combination of clinical epidemiologic and translational research methods.

E-mail:

myersrm [at] chop.edu

Theodore Laetsch, MD

Dr. Laetsch is a pediatric oncologist who provides clinical care and conducts research with the overarching goal of improving treatment options for children with difficult to treat cancers.

E-mail:

laetscht [at] chop.edu

Stephan Kadauke, MD, PhD

Dr. Kadauke is the associate director of the Cell and Gene Therapy Laboratory at CHOP and the medical director of the Cell and Gene Therapy Informatics team. His research focuses on developing novel ways to manufacture cell therapies with the goal of accelerating and broadening patient access to these life-saving therapies.

E-mail:

kadaukes [at] chop.edu

Leyuan Ma, PhD

Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.

E-mail:

mal5 [at] chop.edu

David M. Barrett, MD, PhD

Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.

E-mail:

barrettd [at] chop.edu

Hannah-Lise Tirado Schofield, PhD, ABPP-CN

Dr. Schofield's research focuses on neurocognitive outcomes of oncology treatment. Her areas of interest are acute and long-term neurotoxicities and cognitive sequelae of cellular therapy, including hematopoietic stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy.

E-mail:

schofieldh [at] chop.edu